Tamarix Pharma

Company Overview

Snapshot

Founded in July 2020 by Isaac (Tzachy) Tal, Tamarix Pharma operates with 1–10 employees. The company secured its Seed funding round in January 2021, backed by investors including Israel Biotech Fund and Xenia Venture Capital.

Business overview

Tamarix Pharma is an early-stage biotech company focused on developing novel technologies to restore physiological balance in apoptosis-related diseases. The company's core products, VBIT-4 and VBIT-12, are small molecules designed to target VDAC1 oligomerization, a key mitochondrial process. This unique mechanism of action aims to treat various acute and chronic conditions resulting from apoptotic cell death, operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals and Drugs Discovery & Development.

Company Intelligence Q&A

What is Tamarix Pharma's primary focus?

Tamarix Pharma is an early-stage biotech company focused on developing novel technologies that restore physiological balance in apoptosis-related diseases.

When was Tamarix Pharma founded?

Tamarix Pharma was founded in July 2020.

Who are the founders of Tamarix Pharma?

Isaac (Tzachy) Tal is a founder of Tamarix Pharma.

What are the lead assets of Tamarix Pharma?

The company's lead assets are VBIT-4 and VBIT-12, which are small molecules targeting VDAC1 oligomerization.

What is the status of Tamarix Pharma?

Tamarix Pharma is currently non-active, having ceased operations in May 2023.